Ozempic (semaglutide) affects several important metabolic and digestive processes in the body. Because of this, some users wonder whether it can influence the accuracy of GoBe readings.
Can I wear GoBe while taking Ozempic?
Yes, you can continue using GoBe while taking Ozempic.
The device may still provide useful information about:
hydration;
activity;
sleep;
stress;
general metabolic trends.
How Ozempic may affect GoBe readings
At the moment, HEALBE has not conducted dedicated clinical studies specifically focused on the interaction between Ozempic and GoBe algorithms.
However, from a physiological perspective, semaglutide may affect some metrics because it changes several systems involved in metabolism and digestion.
Ozempic may influence:
insulin and glucagon regulation;
appetite and satiety;
gastric emptying speed;
gastrointestinal motility;
glucose absorption dynamics;
insulin sensitivity.
Since GoBe analyzes physiological responses related to nutrient absorption and metabolism, these changes may affect the accuracy of calorie intake calculations and some other readings.
Possible impact on accuracy
The effect is expected to be highly individual.
For some users, the changes may be minimal. For others, the deviation may become more noticeable, especially during the first weeks after starting treatment.
According to our medical team’s theoretical assessment:
the potential increase in error may reach approximately 20–40% in some cases;
for certain users, the impact may be stronger due to changes in digestion and insulin sensitivity.
Should I continue using GoBe?
Yes. We recommend continuing to wear the device consistently and giving the algorithm some time to adapt to your body’s new metabolic state.
More stable and representative trends may appear several weeks after beginning therapy.
Important note
GoBe is not a medical device and should not be used for diagnosing, treating, or monitoring medical conditions.
If you have concerns related to Ozempic or your health condition, please consult your healthcare provider.
Comments
0 comments
Please sign in to leave a comment.